Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
December 10, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
December 08, 2020 08:30 ET
|
Monopar Therapeutics Inc.
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM WILMETTE, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a...
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
November 12, 2020 09:15 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 Clinical Trial on Track to Start Before Year-endIssuance of New Patents For ValidiveCamsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021 WILMETTE, Ill., Nov. 12,...
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
November 09, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
September 14, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at...
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
September 09, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing...
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
August 19, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit,...
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
August 12, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
August 10, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI),...
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
August 06, 2020 16:05 ET
|
Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...